Clinical Trial Goal
To find out if loncastuximab and rituximab, in combination with standard chemo, is safe and works well to treat high-risk DLBCL
You may be able to join this trial if you:
- Are 18 years old or older
- Have DLBCL that doctors consider high-risk
- Have not been treated with more than 1 cycle of standard chemo. Your doctor can tell you this
- Have not been treated with loncastuximab or rituximab with disease progression in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
DA-EPOCH-R is standard chemo with the drugs cyclophosphamide, doxorubicin, etoposide and vincristine.
Loncastuximab is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Loncastuximab is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- DA-EPOCH-R standard chemo - Given as intravenous (IV) infusions
- Loncastuximab – Given as IV infusions
- Rituximab - Given as IV infusions
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using loncastuximab and rituximab in combination with DA-EPOCH-R standard chemo to treat DLBCL is new and unproven.
Locations
UC San Diego Moores Cancer CenterRECRUITING
San Diego, California
Erin Reid, MD, egreid@health.ucsd.edu
University of California Davis Comprehensive Cancer CenterRECRUITING
Sacramento, California
Selina Laqui, 916-734-0565, slaqui@ucdavis.edu
Sponsors
collaborator: National Cancer Institute (NCI), collaborator: ADC Therapeutics S.A., lead: Joseph Tuscano
